cbdmd.com (YCBD) - Long-Term Debt to Capital Coefficient

cbdMD - graphic logo of issuer YCBD

cbdMD, Inc. (YCBD) is expanding its cannabidiol product line, utilizing a direct-to-consumer online sales model to bypass retail costs. The business faces severe pressure from price wars amid a legal vacuum and the risk of expansion by industry behemoths. The current metric stands at 0.25. Against the backdrop of a market downturn, the firm is optimizing its distribution. This chart illustrates the price action of the asset.

cbdmd.com (YCBD): Long-Term Debt to Equity from 07/04/2022 to 10/29/2026
Signature product of cbdMD Inc.

For cbdMD, Inc., which is developing an extensive warehouse network in the US, the ratio of long-term liabilities to equity serves as an indicator of financial stability. This metric compares the total amount of loans with maturities exceeding one year against total shareholders' equity. It determines the extent to which business development depends on external debt financing. The stability of this ratio confirms the company's ability to maintain seamless logistics for CBD products without the risk of default. An optimal balance here guarantees expansion without a critical debt load.

Analysis of competing companies

Haleon PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital KVUE|VRNA (Verona Pharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital MENS (Jyong Biotech Ltd)|Long-Term Debt to Capital ligand.com LGND|AMRX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient PRGO (Perrigo Company PLC)|Alvotech Corp (ALVO) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Liquidia Inc.|GLPG (Galapagos NV) - Long-Term Debt to Capital|Long-Term Debt to Capital anipharmaceuticals.com|Long-Term Debt to Equity Ratio MNKD (MannKind)|AMPH (Amphastar Pharmaceuticals Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Pacira PCRX|ARS Corp (SPRY) - Long-Term Liabilities to Capital|TBPH: Long-Term Debt to Equity Ratio|aquestive.com - Long-Term Loans to Capital Ratio|SCPH: Long-Term Debt to Capital|Tectonic Therapeutic - Long-Term Debt to Capital Coefficient|TNXP (Tonix Pharmaceuticals Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital SXT China SXTC|Long-Term Debt to Equity Eupraxia Pharmaceuticals (EPRX)|BHST (bioharvest.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital EXOZ (eXoZymes)|ORMP - Long-Term Debt to Equity Ratio|Entera Bio Corp - Long-Term Debt to Capital|HYFT: Long-Term Debt to Equity|ABVC: Long-Term Debt to Capital|Long-Term Debt to Capital Ratio CPIX|Long-Term Debt to Equity Quantum BioPharma|Long-Term Debt to Equity Ratio FibroGen Inc (FGEN)|Long-Term Debt to Capital TELO|ranitherapeutics.com - Long-Term Debt to Capital Ratio|Synergy CHC - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient RLYB|Lexaria - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Pulmatrix Inc PULM|ftzy.com.cn (PTHL) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio APM|LYRA (Lyra Therapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio impactbiomedinc.com (IBO)|Long-Term Debt to Equity Ratio TNFA (TNF Pharmaceuticals)|Ratio of Long-Term Indebtedness to Capital PainReform Ltd|Altamira Therapeutics Ltd. - Long-Term Debt to Equity Ratio|Lipella Pharma (LIPO) - Long-Term Liabilities to Capital|OptiNose, Inc. - Long-Term Debt to Capital|pieris.com (PIRS) - Long-Term Debt to Equity Ratio|PROC: Long-Term Debt to Capital|PTPI (Petros Pharmaceuticals Inc) - Long-Term Debt to Equity|QLI (Qilian International Holding Group Limited) - Long-Term Debt to Capital|Long-Term Debt to Capital Ratio SLRN (ACELYRIN Inc.)|Long-Term Debt to Equity TFF Pharmaceuticals (TFFP)